NPCE - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to NeuroPace's First Quarter 2024 Conference Call.

As a reminder, this call is being recorded. I would now like to turn the call over to Jeremy Feffer from LifeSci Advisors for a few introductory comments. Please go ahead.

Jeremy Feffer

Good afternoon. Thank you for joining us for NeuroPace's First Quarter 2024 Financial and Operating Results Conference Call. quarter will Kuhn, Joel NeuroPace Chief results the we Officer; Chief released call, XXXX. for Rebecca XX, and Financial first today's hear Becker, from Executive financial On March ended Officer. Earlier today, A copy available company's at website release on the neuropace.com. the of press is

of provisions Reform we that commercial These by statements would actual which meaning implied to based future the current expansion, expense harbor results remind reliance statements. the financial the of Litigation including securities laws, like made Before NeuroPace during made you call, and future are relating various expectations pursuant this forecast of to safe within of throughout place revenue clinical trends begin, cause that Accordingly, should those events trials forward-looking market market from make not and conditions, will performance, statements those operating our Any uncertainties statements Private I of XXXX. statements, market projections, opportunity on performance Securities Act predictions and are assumptions. to statements. All these you or and differ and to estimates are business this we undue materially forward-looking those relate and or could management of statements events, forward-looking around estimates forward-looking opportunities, to that call results statements. these that include federal on risks material involve growth or

our the our filed X, on revise with on annual the risks XX-K refer March to quarterly be the SEC year of For Form on filings our the XX-Q future. This any March any section to information, or the conference is XX, and XX, for NeuroPace as the for associated in we with believe please the only with file X, that accurate SEC XXXX, recent reports we obligation, XXXX, filed which required broadcast time-sensitive disclaims descriptions call SEC by business, may May contains XXXX. ended live ended as I this quarter except report and intention otherwise. And to turn other Risk of whether information, now December Officer, more XXXX, statements, Form uncertainties law, including over the detailed SEC new that, Executive or and on with the of with with future report the NeuroPace's call Factors any our or Becker. public or forward-looking will events because Joel Chief financial projections update Joel? of to

Joel Becker

performance business of by followed details today's Kuhn quarter and Thank reviewing you, the CFO, which our XXXX, March turning the out the our XXXX remainder a over quarter performance be I before financial by to ended start our the Jeremy, in and first to present session. for XX, call Rebecca Q&A will good will call afternoon, key everyone. priorities for of the

Let's get started.

the included We last are of XX% million of the $XX.X and from our Medical contributions for for contribution RNS strategic total quarter the Revenue period pleased same year. and growth up SEEG with collaboration. the start the quarter, DIXI to revenue the to compared strong sales XXXX, system from first year-on-year biotechnology reporting products

Over in investing and discipline worked between growth a maintaining the year, line our strong across find past have to top balance business. financial we

success these the of proud are achieved We we of both have fronts. on

$X.X performance. variable this operating strong was result of compensation payments million we cash first a which as held The as example our for included of another to quarter increased burn our

now update, some that drive XXXX, to overview have for September the extended dive XX, performance. We help details quarter, maturity further our flexibility. of are high-level into those the an about of also me term let pleased the to With company's loan this financial today's recently increasing comments date the providing

also we XXXX, the be approximately of review quarter to that market, of near-term longer-term opportunities of we remain epilepsy estimated on growth expand for is reach results opportunities significant $X growth strategy in executing while to the focused and performance annually target market investing U.S., X opportunity our will As than centers which beyond in the $XX in to and our current more are billion business on NeuroPace's and in at patients treating and our first centers execution comprehensive these offers in Level the total billion. bring

through objective increasing treatment Level centers, to patients gap implants was and on increasing utilization of for laser epilepsy in to RNS adoption to generalized level to QX the made system. indications access in as strategy close drug-resistant including help X expanding X expanding centers adoption Our we the RNS referrals and for is of by RNS this epilepsy and outside remain on therapy, expanding patients. Progress focused therapy

One see in metrics the this use this quarter. the total while prescribers. high first is an its quantify we we metric pleased to this active progress to we were not achieve upward trajectory And of and all-time measure number, will continue

training our training in incremental commercial and previously representatives significant field program. now made in-depth our new through also hiring announced moving education These the of are We progress representatives and expansion organization. under

expect majority in half able of the first engage field independent off of and the of second in these activities in year. We year these begin the to to signed activities and the representatives will complete be the half

long-term and will impact of commercial such beyond peer-to-peer the additional of of the Level programs, therapy as This our professional awareness programs. RNS education representatives by webinars, these strategy, in and begun as on accompanied centers. digital placement contracting social representatives access geographies. media activities is that initiation program to activities, targeted such areas, also symposia center an targeted to activities begin the in have have activities including second expanding X phase expect We Pilot

to did results the quarter, referral and in need not X early II of see of Level these programs to identification material on it have first they begun activity in centers. and While rollout well have still we Phase both as the is as additional our implant-related a impact the of monitoring in patients

and where we have representatives our the primarily you look in opportunities DIXI Additionally, revenue center as on lines. have We RNS to project identified along experiencing care geographies we product have these progress. expansion where supporting focused geographies they further sales updating growth that with activities are we added forward in been

is and We with phase is RNS for that This our third is the RNS focused evidence interest on phase. need are system. on drug-resistant the all strategy currently in complete, the effort the the for the of NAUTILUS based patients in idiopathic unmet indications this strong is generalized trial the follow-up that exists implants in further believe significant of expanding the approved Finally, epilepsy. which pivotal study study

endpoint XX study months post effectiveness a system RNS FDA-approved highly approved, As evaluation a implant. for and an reminder, represent the potential If would NAUTILUS device be of the safety to meaningful generalized first trial requires expansion has This a an evaluation market opportunity. indication epilepsy. with primary our the

we revenue and electrodes CECs. is with In products has RNS provides to addition offering with complementary system, epilepsy. exclusive the their to system, for from highly commercial also call the sell RNS continue opportunity physicians which to This Medical a at see our had diagnostic our on to partnership and team our our with related DIXI team an growth success our to market additional sales

is turn for of to the now biotechnology groundbreaking system the ability of quarter used the with generate an milestone strategic another We progress, quarter can company Lastly, that me additional analyze inform collaboration the to which example completed RNS operational fourth value XXXX, to let we first XXXX. that XXXX. review data, first of pleased in collaboration collect as financial the believe in important to of which overview our proven results entered treatment with then provide Rebecca? over Rebecca and can its our this insights our is are strategies. With help of quarter an into call we a the through

Rebecca Kuhn

was quarter first driven million you, of of compared XXXX the NeuroPace was growth representing $XX.X Joel. RNS quarter the million, by sales Thank system. revenue XXXX. for This our $XX.X for XX% to increased of primarily of growth first

margin implant first compared period continued We XXXX to the year meaningful quarter Medical compared growth the XX.X% of first of also of the DIXI revenue. Gross total sales XXXX. approximately to for XX.X% from generated Replacement revenue represented in products. quarter decline and to same X% last revenue was of

and increase more produced fixed due were over units. Our the costs products our spread gross manufacturing units to overhead improved margin for R&S as sold in

contribution reflects due as severance to the by to of the XXXX. period revenue in the million revenue of gross recent operating expenses. This prior was our of with driving the in $XX.X the as lower on expenses expenses, prior million $X.X well of by $XX.X period of the This largely driven costs quarters, increase increase the prior increase expense growth same with also million Consistent in personnel-related gross compared our the quarter in the period. company a year. R&D personnel-related an performance offset relative in from as in our compared SG&A margin cash. the quarter $XX.X focus was of XXXX operating $X.X XXXX with The for and increase due DIXI driven period. with operating first quarter personnel collaboration expenses in commercial first Our also in changes. Total a increase managing in were primarily This year margin XXXX distribution lower made was expenses year compared million were to effectively $XX.X SG&A the primarily while million million of with was by same percentage was products. R&D margin team in biotech expense quarter first XXXX. partially both the expenses and to our of first gross Medical

first which of year year XXXX to compared in in continue quarter $X the compared to in of XXXX Net million the of prior million million objectives from on $X.X first appropriate was $X.X period. in million the with balance $X.X with period. We first first to finding $X.X was the expect continue XXXX million throughout we of recorded We the for in XXXX. quarter to the resource focus prior these XXXX. Loss the $XX.X quarter expense quarter allocation compared million interest loss of operations

of disciplined in million the As $X.X million first compared have management expense in maintained burn to discussed of strategy, resulting quarter $X.X we cash the of first in previously, a XXXX. quarter XXXX

As the to year timing of flow of fiscal payments. of tends primarily the due first cash the year our quarter the be reminder, quarter a to compensation-related highest

was Our investments balance XX, million. cash and as of short-term XXXX March $XX.X

March by We finalized we XX, XX, as September totaled believe one $XX agreement extend to financial XXXX. Our this position. of of our our announced year borrowings improves lender final an maturity that today with XXXX. the further We million our to overall extension long-term debt

system Regarding expect growth increase with expected is growth revenue continue to of our to RNS $XX for in Medical to a approximately products an by an make we of million XX%. mostly meaningful million, range sales be a to to total This continuing sales of DIXI from increase annual $XX XXXX, to guidance be of XX% in our driven contribution.

fluctuations expect may gross XXXX, a to for we overall to variability in to proportion their to other of margin see factors. of small Medical be range DIXI and revenue due We in revenue our XX% XX% although

$XX XXXX and remarks. in Joel? over expense. I back We to like $XX compensation, million Joel range expect the now million turn $XX operating for including would approximately closing call to noncash expenses between a million to stock-based for

Joel Becker

to open you, forward Thank to are I our over execute will I to help the RNS on would like the to by throughout on expanding XXXX. This and strategy growth look our prepared NeuroPace, remarks. the epilepsy concludes to focused close for on operator At questions. who Rebecca. drug-resistant call for to turn access our treatment the the now we progress you to call updating patients continuing gap opportunity therapy.

Operator

[Operator Partners. Leerink Kratky Instructions] comes line Your Mike the first from of from question

Michael Kratky

into at I you current some between provide factored a maybe additional it's your on little commercial But to on changes assumptions be based you XQ what range from the this how the and helping really just RNS color that that here? is in level XQ? you difficult DIXI experience guidance bit are revenue seeing Can might you answer. shape product any saw to in point know saw being

Joel Becker

perspective. here comments, from good said So lines year-on-year we across growth really in our a saw contributions prepared as we product

we And or that, account well that that think the we the as care about we into or with underway, when we rest mentioned organizational take that's so the year then activities the have prescribers. activities look that number as a traction expansion of of we whether as at the

all what the about we're about So how particular, some there half that the replacement Obviously, we we take into in that thinking of our our there's generate today view DIXI. performance talked well the all when roll headwinds ago, like of of in the being of again, and guidance best the to the RNS with for maintained feel year we issued represents good rest revenue that the something in as the particular sales couple of terms here, systems initial year. really in cycle through as with business the sales expect both of we that But we from together, that year. here in for comments with, as first and we a the we months well contribution

Michael Kratky

follow-up just one maybe that. to And

saw [ the the ultimately maintain really in potentially a range guidance had was year. same and that's You in were far pause nice that beat range Can whether ] same factors XQ you so anything you the lot being initially? XQ guidance confirm for raising that you just the of giving there a about considered or

Joel Becker

we a of of guidance, and QX. that here about here too seen everything when that when we and quarter year. we maintain about then that to the mentioned, as you And And as it's and view ago long the confirm QX really, just we've we're year. so -- we're forward else full guidance and talking guidance talking were and set the today the rest What not we QX look for with

and those both So well going at we well. factors of here as number year. the the again, then different beginning it in of all the here through look of headwinds remainder noted with front us as year couple saw the of excited of we We're, a a contemplated about forward when at opportunities what combination a we really of as had the is that

Operator

next comes from the Markets. question Lake Capital of Your line Takkinen Frank Street from

Frank Takkinen

to you where what was could of hoping are to on refresh are I bit with and on sites? they I going up prescribers a Or Joel. I comment on new I more prescribers, using users hoping the those how then they was give follow you you're said typically that, those your kind us about who now from up? sites color new just give not existing little know but maybe And are are mean scale technology? new the quantify

Joel Becker

And the has way and Frank. the yes, prescriber metric. been tracking question, in Great excited we see numbers that that to new there were

associated the at it's number that So that an with RNS past look way implant the initial prescribers we that, the XX been months. of over have

a centers. the as well of prescriber we look is adoption at those look both and when coming So from, at it's within kind of current where new combination as

So we where both. coming increased we're given from of But at see the of a nature lot adoption today, them is it within current centers.

in new there's get centers of users we're expansion and users But well. So we component users adoption as of new centers a today. within new and also present which of

Frank Takkinen

Okay. about as training users just as how process do ramped And prescriber? And new then that, like? to the start of the they are think overall half second you average about thinking up? when What's maybe procedures how the many do the

Joel Becker

question. great a Yes,

to ramp you for them a imagine, take as bit so it And up. new have you user, can might little when a

all neuromodulation so and the then RNS with with basics start in of ] the customers, incorporate can practice and their into really they and their foundations we and that And just do [ how as scale new therapy up. it practice we

so and people to and fashion patients really So adoption terms over well to and practice and implementation how RNS as take those we there developed in described and for we of their a it understood -- that that through scale a training have to both fits model here. up education how in patient manage time we've process understanding selection as really reproducible and work well where process

Frank Takkinen

sneak maybe And more just in. if then one I could

milestone payment million that? agreement, with portion $X.X what you not the you was? congrats contract that received achievement. whether of Can milestone quantify on On value And a or the total the biotech

Rebecca Kuhn

give Sure, Frank. you We'll little try and a more color.

quarters So payments is reminder, and X $X.X the a up the over as a total total revenue just anticipated collaboration of the of to million.

not occurs variations. that terribly So It's the dramatic. some revenue have payments and over time the

but received specifics, you give way the along to that there going recognized payments of the course, are revenue and, not we're So along yes, are way.

helpful. hope I So that's

Operator

next Wells line the Vik question of Your comes Fargo. from Chopra from

Vikramjeet Chopra

guidance. a follow-up on had question I also

beat. help raise for the follow-up, I pretty it that? had then margin gross year? Maybe please. what color gross the additional And some guide maybe us how to had You nice drove a not Why just about for think just year? on margin And a the

Rebecca Kuhn

Sure.

Vik, largely larger margin, units, units. gross year-over-year, number over increased overhead sold. that our So are our increase to due spread and in the units a produced of That R&S means fixed costs

there. case, leverage some margin see has by then see gross reduced margin gross continue We biotech DIXI. the is And to always we contribution did gross been is the collaboration. reduce from as from lower the So nice our margin our

Vikramjeet Chopra

follow-up just providing with where you the had was for the help I you'll to metrics progress? us be pilot are us the programs Maybe then question what CARE. on And track Project and understand

Joel Becker

terms So initiating of really activities. programs of just two of in activities professional education the in One is some buckets the in now. of right specifics programs we're

foundations of options for then process engaging on within education of treatment in as as training some a users of topics new plan with previous accounts, But professional So neuromodulation here educational those in the with initiating taking one targeted targeted activities earlier practices. RNS education -- pilot new of users. their our we've about including same we're as I've RNS here and a terms and in initiation these question in approach professional discussed therapy activities of including programs, were centers we're of calls, symposia program. We mentioned practice and webinars. I and within those when the and to the the

part along go with patient of to patient really things as programming, establishing management as So program. their they learn well selection is this that of the understand all reimbursement,

activities. as the well as practice education peer-to-peer professional well as clinical as So development

RNS start-up early and the help in can guide through So with centers process. using who peers they are experienced

that's matched a in related geographies well So of number center initiation here of work as a as our as activities commercial contracting fair digital made some and and bit to marketing training of regard well, social been expansion the media with organization. activities. And including incremental for targeted a commercially related of then I from perspective here progress had to mentioned hiring with we the initial

care position the well on trained some that have in activities commercial been executing we've So geographies targeted well. as reps those been of in getting and as

then the about regard are pipeline centers those building of and the So the the major through our each of the of is really it way the that. buckets. With really call processes of think throughput. then -- and mentioned contracting and it of some of development these timing I starts contracting activities kind starting activities from contact some ability the way it's the -- to kind just of that some track of really I off to kind with to and of within pacing metrics, and the and And the sales initial everything

also moving the then completion and process of We identification process and education obviously, measure the patients training and implants. the to patient and education then

of So X Level not these as RNS through centers. including X patients referrals who additional that over good but of be may of direct and centers rate outside then we into well centers Level all in time and as up track be patients implant measure referred can

development then it think how these execution about way So way pipeline centers. maybe a each for we're targeted I And managing steps of think to that's the internally. of along it's the and just in each it, helpful the

Operator

from next the JPMorgan. line question Robbie Marcus Your of comes from

Lilia-Celine Lozada

second Anything this and quarter in was [ I mind quick that for sort share Lily on should how should second think I it then fair million, ], puts And takes $XX.X for place a follow-up. be quarter Street for we keeping be? about that Robbie. at through about cadence to of had we a And fourth thinking can any of quarter? for is you be year? on is the This

Joel Becker

balance some of there We're the calendarization of with of some then the sometimes calendarization where beginning -- that of And QX see with be past well vacation quarterly, bit about see of but is see kind might times out the of for pointed tend don't have like comment cadence during some maybe talked of the Thanksgiving slowdowns meeting, in that maybe Year guiding is between in in holiday do we many, I just kind from year society we in We've of toward go of kind vacations some the as particular a We and Meeting. the some could couple that Program holidays to year. the week business, summer a and this holiday you not epilepsy of Christmas, the then on traditional but other we for kind Rebecca the summer business, breaks. first of then period American the to times December. We others. and the associated that and end past the of and and impact. the the customer comment us, can in little Epilepsy seasonality AES Thanksgiving, and we of QX, seasonality see summer this we cadence kind for have in biggest Society That's the invite

of we long not to Thanksgiving into AES too of then kind go right kind and Christmas. So from

kind be different the can even of based So is times, those that guess half that QX going of thing calendarized of that, though kind in impacted. I events more mentioned the on different there there on at cadence have a obviously business up. and are of of kind I'd second the of some that little things though, top can been cover

little more not the bit of holidays cadence to may in for quarterly and that, of Thanksgiving us of a be helpful tend the I from mid-summer period be entirely can AES the Christmas in So that model. some times your QX recognize perspective. be impacted of building But time that terms a kind

Lilia-Celine Lozada

revenues. just then replacement on And

half heard the that those headwinds the you of to year. I first strongest in expect think you mention I be

item color growing be expect the half and beyond? those moderate on in headwinds to Any how about you're should would that we helpful. So line second thinking

Rebecca Kuhn

Sure.

very good Yes. a listener, You're

year. year sure in reduced what but replacement pronounced continue, can whole, likely is second more so that less the continue that, a that's the that not -- trend that shared true. I the in exactly, to For before and will do that, we've basically to and but of half the revenue expect of that that to be first the half I'm as the in believe will be year add we

Operator

from Fitzgerald. Osborn question of from the comes line Cantor Ross next Your

Ross Osborn

So in to of hybrid your surgery? any be if terms offering would your for undergone that patient population, see the case patients use with traction curious have RNS of seeing you're

Joel Becker

please I'm We sorry, Ross, you up repeat broke that just question? could a little bit there.

Ross Osborn

Sure.

you're hybrid Just with therapy any seeing of have your that curious if surgery? traction patients the for use RNS case undergone

Joel Becker

or with neuromodulation not examples patients in of going where, to we hear with of of and either/or great ideal question. think That's candidates XX% about people in the for surgery and have really maybe particular examples think selection are and do where, mutually we an kind bit as and that's exclusive, either device thought of and going RNS. have kind as going resection really for R&S put that first, call many Level were would area first-line comprehensive the the of we And on focus part population reality is patient of past, patient further a not about the in identification of modern were do then cases, little in the the of which folks centers story, particular, I classic in they resect. a to resection And a tell the and procedure, epilepsy to about traditional in resection therapy X resection surgery particular example, that in what in RNS our then

A so patients resection multifocal patient population. plus origination, And ] of surgery. approach be two, do to to we hybrid using focal or RNS then kind network number a but modern a one, Number approach the therapy hybrid may for of component RNS key as stimulation see also story that who inform classic [ where, resection

that's folks we that and when patient So and selection RNS. something see about we we're that something identification with absolutely talking with about talk

Ross Osborn

fair accelerating. to thinking you year? we revenue this that of Is are see implant second activities assume half second in more we should the into then quarter? be should And of the it model terms mentioned during coming Or CARE,

Joel Becker

Yes.

implants activities as that centers seeing for implant underway I Phase identify or X to we're well well. Level that is aren't we're but they do patients are completely monitoring, ready referral to seeing II think to as do be yet, need what referring X centers seeing are rather, Level implant we're just patients referred for or for underway and for either getting

do we we of our year, impact the as expand program pilot as well half both in rep as the terms So and expect in in that the second throughout will activities particular, the go activities of effectiveness year.

we're what focused of the really half that's and activities second so those And watching is the on the in of activities those and impact year.

Operator

from Your from next Michael comes of question Research. Polark the Wolfe line

Michael Polark

of the itself? when kind of this? the you Or the it sales But not the about one is be. steer your first following DIXI. topic DIXI of XX had months, big wondering have Do was just kind might quarter I guidance is focus you're did good you DIXI more a good around likely taking good had what sense run use at or Or is this grow the electrodes is this a as to of deal. the these of the that what then in for to because to I'm kind how level and growing? the good. And It's but year. is you product be on the of force? expectation Any be of of long-term would it kind disclosure would this vision am for I asking than so to the if annualized into asking I admittedly, for that share? model blocks I'm of a expect kind increasing now. We this it's Is for case market now kind grow, do building think the color the supposed growth what X-year

Joel Becker

about And to centers guiding And And as SEEG in as then both on response we as and continue pursue has having a for expect will opportunity That's where that in we products. And where think as product has a strategy a SEEG, next develop we've us what borne are strong well the presence monitoring for places have specifically use the the our when our can we other presence products absolutely and presence. we some of for and from performance an clinical strong in places market story places the of great these with a but growth and portfolio. those take we that there's utilization, and customer grow expectations using to I neuromodulation story. We usage patients in and strong the growing customers as comment leverage expectations SEEG. won't are those of significant be leverage we story talking tell three II out of and product comprehensive centers Mike, the to in epilepsy for I years, and the to get the of really the help Well, products folks DIXI share of DIXI trend SEEG you of look the line the they presence. offer think terms about those clinically. in where terms in DIXI where DIXI emerging that centers to we presence the to here behind in seen on part see can tell grow see as we opportunity of Phase perspective

therapy more that's to with as us places for present where for opportunity an well. than look RNS also We be

then And so also leverage diagnostic the and RNS of strong of been with here as RNS ability opportunity for SEEG identification product a products take DIXI the vertically -- both a both bag, the move into in upstream presence patient have provide then to share an a both in presence grow the places further of terms think it's perspective. to us kind process, from well well for in sell, stronger but of to as great that as available to as there's centers strategy terms having integrate terms market I has strong where that to overall us our in an

leverage grow and we we think lot of a points of So expect there's DIXI. there, to

Operator

Morgan of from Drew last comes Stanley. from Your line question Ranieri the

Andrew Ranieri

understand I has but product ticked a what strategy, it's your about even development just standpoint? is spending quarters, just from R&D standpoint Maybe last up a to maybe else in talk like money you're development over NAUTILUS clinical now. up, like the just wrapped on follow-up us few R&D or there your spending

Joel Becker

our you well as investments research in and development. product clinical research as mentioned, product within R&D, As in

didn't commercial I investments involved on Lennox-Gastaut we're in from that medium-term ] that longer and and to that with And know it as that of in in AI NAUTILUS, well. development you the critical data and management the [ engaged But data part the the a comment significant between about more the study here forward. here investing So our middle as well the stage to well. And then NAUTILUS, of call, investing today, that I and working as investment now. an we're mentioned monitoring in term from and last as we're expect we're and you us business about perspective is study strike bit business, as while we're in well obviously, but optimizing in perspective execution be but research follow-up that I initiatives going say for up we've clinical good development would we're balance and development as as in operating discipline. just And first mentioned, wrapped did as punchline a the maintaining well with in of product a focus investments

some in and you're a other operating areas. of continue look control line the to what discipline and if think investment is to R&D, and organization commercial seeing from expansion our all top in at focus on focused drive in expense I statement, investment us you so real strong here, income And areas the some

Andrew Ranieri

general. the that And and procedure highlight? that maybe you environment in the Anything one diagnostic funnel into in environment quarter just on anything And the second quarter? seeing first you're would

Joel Becker

consistency seen robustness regard generally. in from individual I would pipeline see have kind seen we with of and what for we're that few to more Just the what a of patients here centers past and and say of strong particular, pipeline and QX, we've quarters, the good from seeing good

good the looks Would So that, you I consistent. think add Rebecca? pipeline to and anything

Rebecca Kuhn

No.

pipeline. that. volumes we're And we're ] emphasis where pipeline the a see think we [ the normalized of and we're I EMU I pleased what and lot patients with in on is. We we pleased generally, think placed just seeing track patient

positive. are trends So

Operator

at proceed. Joel this time Mr. There are you. further Becker. Please no Thank questions

Joel Becker

to Thank you, our today. QX everyone, for listening call XXXX

look to at you. on updating the strategy earlier, executing throughout focused mentioned opportunity and therapy. to about I our here and As drug-resistant about on excited growth gap XXXX. everyone for NeuroPace, access doing to excited expanding we're the We're treatment forward help progress our on so. close to patients epilepsy Thank We by RNS

Operator

for you. Thank concludes you our for Thank conference This participating. all today.

all disconnect. You may

NeuroPace (NPCE) 8 May 242024 Q1 Earnings call transcript